JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador en el periodo 1986-2013
Harvard University
Cambridge, Estados UnidosPublicaciones en colaboración con investigadores/as de Harvard University (10)
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
2009
-
A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP
CLINICAL LYMPHOMA & MYELOMA
-
Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone
CLINICAL LYMPHOMA & MYELOMA
-
Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial
CLINICAL LYMPHOMA & MYELOMA
-
Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma
CLINICAL LYMPHOMA & MYELOMA
-
Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau
CLINICAL LYMPHOMA & MYELOMA
-
VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM
CLINICAL LYMPHOMA & MYELOMA
-
VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study
CLINICAL LYMPHOMA & MYELOMA
2003
-
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group
British Journal of Haematology, Vol. 121, Núm. 5, pp. 749-757